CD274 and metabolic dysfunction-associated steatohepatitis: Clinical trial studies also showed that anti-programmed death-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) treatment decreased the overall survival (OS) of human patients with NASH-induced HCC compared to non-NASH-induced HCC patients (22).